Is Atezolizumab Plus Chemotherapy Effective for Urothelial Carcinoma?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
At the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, from September 27 to October 1, 2019, Enrique Grande presented the results of the IMvigor130 Phase 3 clinical trial. This trial investigated the efficacy and safety of Atezolizumab (an anti-PD-L1 antibody) in combination with platinum-based chemotherapy for patients with untreated locally advanced or metastatic urothelial carcinoma.
Study Design: IMvigor130 Phase 3 Trial
The IMvigor130 trial randomized 1,213 patients with untreated locally advanced or metastatic urothelial carcinoma into three groups:
- Atezolizumab + Chemotherapy Group (Atezolizumab + Gemcitabine + Carboplatin/Cisplatin, N=447)
- Atezolizumab Monotherapy Group (N=369)
- Placebo Group (Placebo + Chemotherapy, N=397)
The primary endpoints were progression-free survival (PFS) and overall survival (OS).
Key Results (Median Follow-up of 11.8 Months)
Progression-Free Survival (PFS)
- Atezolizumab + Chemotherapy: 8.2 months
- Placebo + Chemotherapy: 6.3 months
- The combination group showed an 18% reduction in the risk of progression (Hazard Ratio [HR] = 0.82).
Overall Survival (OS)
- Atezolizumab + Chemotherapy: 16.0 months
- Placebo + Chemotherapy: 13.4 months
- Although there was a 17% reduction in the risk of death (HR = 0.83), the improvement was not statistically significant at this interim analysis.
- The Atezolizumab monotherapy group had a median OS of 13.1 months, showing a 2% increase in risk compared to the placebo group (HR = 1.02).
Objective Response Rate (ORR)
- Atezolizumab + Chemotherapy: 47% (Complete Response [CR]: 13%)
- Atezolizumab Monotherapy: 23% (CR: 6%)
- Placebo + Chemotherapy: 44% (CR: 7%)
Safety and Conclusions
The safety profile of Atezolizumab in this trial was consistent with previous clinical studies, with no new safety signals observed. Discontinuation rates due to adverse events were 34% in the combination group, 6% in the monotherapy group, and 34% in the placebo group.
Enrique Grande concluded that Atezolizumab plus platinum-based chemotherapy significantly improved PFS in patients with untreated locally advanced or metastatic urothelial carcinoma, with a manageable safety profile.
Note: The information provided by "Medical Supporter" is for reference only and does not constitute a recommendation for any specific treatment or clinical trial. Please consult with your medical team for personalized advice.
Source: Adding Atezolizumab to Front-Line Platinum-Based Chemotherapy Improves Progression-Free Survival in mUC [ESMO 2019 Oncology News]
#UrothelialCarcinoma #Atezolizumab #Tecentriq #Immunotherapy
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4